Roche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their newest drugs by 61% on average to get them reimbursed in China, according to a repo
Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.
With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants
